BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17154097)

  • 1. [Childhood Graves' disease].
    Sasaki N; Sato K
    Nihon Rinsho; 2006 Dec; 64(12):2308-11. PubMed ID: 17154097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
    Kubota S
    Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graves' disease in children and adolescents: response to long-term treatment.
    Barrio R; López-Capapé M; Martinez-Badás I; Carrillo A; Moreno JC; Alonso M
    Acta Paediatr; 2005 Nov; 94(11):1583-9. PubMed ID: 16303698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The propylthiouracil dilemma.
    Glinoer D; Cooper DS
    Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):402-7. PubMed ID: 22820213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pancytopenia associated with antithyroid drugs in a patient with Graves' disease and chronic renal failure.
    Macia M; Méndez M; Fernández J; Riverol A; Rios
    Clin Nephrol; 1997 Feb; 47(2):129. PubMed ID: 9049463
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.
    Molnár I; Szentmiklósi JA; Gesztelyi R; Somogyiné-Vári É
    Clin Exp Med; 2019 May; 19(2):245-254. PubMed ID: 30610492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
    Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
    Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
    J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil.
    Momotani N; Yamashita R; Makino F; Noh JY; Ishikawa N; Ito K
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):177-81. PubMed ID: 10931098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
    Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current problems in the treatment of Graves' disease in pregnancy and in lactation].
    Momotani N
    Nihon Rinsho; 2006 Dec; 64(12):2297-302. PubMed ID: 17154095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity and cutaneous reactions after antithyroid drug administration.
    Otsuka F; Noh JY; Chino T; Shimizu T; Mukasa K; Ito K; Ito K; Taniyama M
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):310-5. PubMed ID: 22332800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.
    Santos RB; Romaldini JH; Ward LS
    Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.